Design, Sythesis And Testing Of Anti-Rhinovirus Agents

Rhinoviruses are the common cause of infections in human. Human rhinoviruses infections cause nasopharyngealsyndrome (the "common cold") in general population of all ages. Although rhinovirus infection is self-limited, complications could still occur in patients with asthma, congestive heart failure, bronchiectasis, and cystic fibrosis. The absence of effective vaccines for most viral infections highlights an urgent necessity for the design and development of effective antiviral drugs.Due to the advancement in virology since the late 1980s, several key events in the viral life cycle have been well delineated and a number of molecular targets have been validated, culminating in the emergence of many new antiviral drugs in recent years. Inhibitors against rhinoviruses, responsible for about half of the human common colds, are currently under active investigation. Agents targeted at viralproteinl (VP1), a relatively conserved capsid structure mediating viral adsorption/uncoating process, is of great potential to become antirhinovirus drugs. Pirodavir(R77975) was discovered at Janssen Research Foundation. Both compounds possessed significant activity in inhibiting the replication of many rhinovirus serotypes, so Pirodavir(R77975) is wished to an effective and low side...